ABIOMED, Inc. (NASDAQ:ABMD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August24, 2017, Michael J. Tomsicek resigned his position as Vice President, Chief Financial Officer and Treasurer of ABIOMED, Inc. (the “Company”). Effective immediately, Mr.Tomsicek ceased serving as the Company’s principal financial officer and principal accounting officer.
The Company’s current Vice President, Corporate Controller, Ian McLeod, age 52 will serve as the Company’s interim principal financial officer and principal accounting officer. Mr.McLeod has served in his current position at the Company since November 2007. Prior to joining the Company, Mr.McLeod served as the Corporate Controller and other financial reporting roles at Idenix Pharmaceuticals from March 2002 through November 2007. Mr.McLeod is a Certified Public Accountant and worked over 8 years in public accounting. Mr.McLeod has a Bachelor of Arts from the University of Western Ontario and a Master of Business Administration from McMaster University.
There are no arrangements or understandings between Mr.McLeod and any other persons to which he became the Company’s principal financial officer and principal accounting officer. There is no family relationship between Mr.McLeod and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer of the Company. The Company has not entered into any transactions with Mr.McLeod that would require disclosure to Item404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.
The Company is maintaining its fiscal year 2018 revenue guidance of $560 million to $575 million and its fiscal year guidance for GAAP operating margin in the range of 22% to 24%.
Item 5.02 Other Events
On August28, 2017, the Company issued a press release announcing Mr.Tomsicek’s departure. The Company also announced that Robert L. Bowen, the Company’s previous chief financial officer, will return to the Company as a consultant to support the organization while it conducts an external search for a permanent Chief Financial Officer. The press release relating to the matters described in this Item 5.02 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 5.02 Financial Statements and Exhibits
|99.1||Press release, dated August 28, 2017|
ABIOMED INC ExhibitEX-99.1 2 d448739dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial Officer as Consultant DANVERS,…To view the full exhibit click
About ABIOMED, Inc. (NASDAQ:ABMD)
ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.